ArticleJournal of lipids2011
The Dynamics of Oxidized LDL during Atherogenesis.
Article in Journal of lipids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 125 citations in OpenAlex.
- Changes in LDL Oxidative Status and Oxidative and Inflammatory Gene Expression after Red Wine Intake in Healthy People: A Randomized Trial.Mediators of inflammation · 2015Trial
- Intake of red wine in different meals modulates oxidized LDL level, oxidative and inflammatory gene expression in healthy people: a randomized crossover trial.Oxidative medicine and cellular longevity · 2014Trial
- Modulating Oxidative Stress and Inflammation in Elders: The MOXIE Study.Journal of nutrition in gerontology and geriatricsTrial
- Lower Micronutrient Intake in Patients with Coronary Artery Disease: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy.Current opinion in lipidology · 2025Review
- Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE.Drugs in context · 2025Article
- Effect ofPreventive nutrition and food science · 2024Article
- Radical Oxygen Species, Oxidized Low-Density Lipoproteins, and Lectin-like Oxidized Low-Density Lipoprotein Receptor 1: A Vicious Circle in Atherosclerotic Process.Antioxidants (Basel, Switzerland) · 2024Review
- Non-oxidative Modified Low-density Lipoproteins: The Underappreciated Risk Factors for Atherosclerosis.Current medicinal chemistry · 2024Review
- Regulation of gasdermins in pyroptosis and cytokine release.Advances in immunology · 2023Article
- Paraoxonase 1 and atherosclerosis.Frontiers in cardiovascular medicine · 2023Review
- Mitochondrial Iron Metabolism: The Crucial Actors in Diseases.Molecules (Basel, Switzerland) · 2022Review
- Obstructive Sleep Apnoea and Lipid Metabolism: The Summary of Evidence and Future Perspectives in the Pathophysiology of OSA-Associated Dyslipidaemia.Biomedicines · 2022Review
- Adaptive and maladaptive roles of lipid droplets in health and disease.American journal of physiology. Cell physiology · 2022Review
- A biomathematical model of atherosclerosis in mice.PloS one · 2022Article
- Biomarkers of Oxidative Stress Tethered to Cardiovascular Diseases.Oxidative medicine and cellular longevity · 2022Review
- Oxidized low density lipoprotein in the liver causes decreased permeability of liver lymphatic- but not liver sinusoidal-endothelial cellsFrontiers in physiology · 2022Article
- Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.Membranes · 2021Review
- Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis.Journal of clinical medicine · 2021Review
- Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence indicates that oxidized low-density lipoprotein (OxLDL) is a useful marker for cardiovascular disease. The uptake of OxLDL by scavenger receptors leads to the accumulation of cholesterol within the foam cells of atherosclerotic lesions. OxLDL has many stimulatory effects on vascular cells, and the presence of OxLDL in circulating blood has been established. According to the classical hypothesis, OxLDL accumulates in the atherosclerotic lesions over a long duration, leading to advanced lesions. However, recent studies on time-course changes of OxLDL in vivo raised a possibility that OxLDL can be transferred between the lesions and the circulation. In this paper, the in vivo dynamics of OxLDL are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.